From Nasdaq: 2025-02-16 09:45:00

Axsome Therapeutics (NASDAQ: AXSM) has seen a 55% increase in its stock price this year, raising questions about its long-term performance. The recent settlement of a patent lawsuit over Auvelity with Teva Pharmaceutical Industries has boosted Axsome’s prospects. With strong revenue growth from Auvelity and Sunosi, the company expects a 42% increase in revenue for 2024. Axsome is also making progress with new medicines, including a potential treatment for Alzheimer’s disease. The biotech company shows promise for solid returns in the future, making it a potentially lucrative investment opportunity.



Read more at Nasdaq: This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?